Madrigal gets FDA nod for Rezdiffra to treat liver scarring patients
The accelerated approval was based on the findings from the ongoing Phase 3 MAESTRO-NASH trial in which Rezdiffra…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
15 Mar 24
The accelerated approval was based on the findings from the ongoing Phase 3 MAESTRO-NASH trial in which Rezdiffra…
15 Mar 24
The FDA has approved Breyanzi to treat adult patients with relapsed or refractory chronic lymphocytic leukemia or small…
15 Mar 24
The approval was based on the results from the Phase 3 RATIONALE 302 study in which Tevimbra indicated…
15 Mar 24
As a part of this collaboration, Biocon Biologics will continue to leverage Eris’ strong commercial footprint to significantly…
15 Mar 24
The fully managed cloud service will enable the healthcare provider to streamline operations, consolidate IT systems maintenance, reinforce…
14 Mar 24
The approval of the IBAT inhibitor was based on findings from the Phase 3 MARCH study which included…
14 Mar 24
Under the agreement, Novartis made fixed payments to fully fund IFM Due’s research and development expenses for the…
13 Mar 24
The results of the late-stage trial showed a statistically significant and clinically meaningful changes in overall survival and…
12 Mar 24
The orphan drug exclusivity grants the drug seven years of US market exclusivity in its approved indication and…
12 Mar 24
The asset sale consists of the majority of the company's workforce and most of its clinical equipment and…